- The FDA has approved Steqeyma, a biosimilar of Johnson & Johnson’s (NYSE:JNJ) blockbuster drug Stelara.
- Steqeyma, which was developed by South Korea’s Celltrion, was approved for the treatment of adults with Crohn’s disease and ulcerative colitis and for adults and children aged
FDA approves Celltrion’s biosimilar of J&J’s Stelara
